A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 4, 2021

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Lenvatinib

Lenvatinib capsules.

Trial Locations (10)

302019

Somani Hospital, Jaipur

400012

Tata Memorial Hospital, Mumbai

411004

LMMF's Deenanath Mangeshkar Hospital & Research Center, Pune

411013

Noble Hospital, Pune

422002

HCG Manavata Cancer Centre, Nashik

422005

Shatabdi Hospital, Nashik

422009

Apex Wellness Hospital, Nashik

560027

HCG Comprehensive Cancer Care Hospital, Bangalore

625107

Meenakshi Mission Hospital, Madurai

700054

Apollo Gleneagles Hospital Limited, Kolkata

All Listed Sponsors
lead

Eisai Pharmaceuticals India Pvt. Ltd

INDUSTRY

NCT04297254 - A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC | Biotech Hunter | Biotech Hunter